Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406108 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136100 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136102 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL17001389 | 0.89 | DPP4 (0.59) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL18774237 | 0.87 | DPP4 (0.64) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15166497 | 0.87 | DPP4 (0.57) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15080519 | 0.87 | DPP4 (0.46) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL16750213 | 0.86 | DPP4 (0.56) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL13637938 | 0.86 | DPP4 (0.50) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL21497518 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111204094-A | TPEE acoustic film and production method thereof | 苏州市新广益电子有限公司 | 2020-05-29 | — | — | CN | claimed |
| US-8476437-B2 | Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2013-07-02 | — | — | US | claimed |
| US-20110213149-A1 | PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-09-01 | — | — | US | claimed |
| EP-2331545-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| US-20100274017-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-28 | — | — | US | claimed |
| EP-2220093-A2 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Dr. Reddy's Laboratories Ltd. (IN) | 2010-08-25 | — | — | EP | claimed |
| WO-2010032264-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| WO-2009085990-A2 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | WO | claimed |
| WO-2023181046-A1 | RECYCLABLE BIOCATALYTIC PROCESS FOR PREPARATION OF SITAGLIPTIN | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| US-20220048917-A1 | HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN VIA RHODIUM CATALYZED ASYMMETRIC HYDROGENATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-02-17 | — | — | US | disclosed |
| US-11174266-B2 | Efficient process for the preparation of sitagliptin | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2021-11-16 | — | — | US | disclosed |
| US-20210061808-A1 | NEW EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2021-03-04 | — | — | US | disclosed |
| WO-2020121321-A1 | HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN VIA RHODIUM CATALYZED ASYMMETRIC HYDROGENATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-06-18 | — | — | WO | disclosed |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | LEE PHARMA LIMITED (IN) | 2019-10-22 | — | — | US | disclosed |
| WO-2006033848-A1 | AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005072530-A1 | NOVEL CRYSTALLINE SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005030127-A2 | NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK SHARP & DOHME LLC | 2005-02-10 | — | — | US | disclosed |
| WO-2005003135-A1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004085378-A1 | PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION | MERCK & CO. INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061808-A1 | NEW EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 4/4885DPP7 3/4885 |
| US-11174266-B2 | Efficient process for the preparation of sitagliptin | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-20220048917-A1 | HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF SITAGLIPTIN VIA RHODIUM CATALYZED ASYMMETRIC HYDROGENATION | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 14/4885DPP7 2/4885 |
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP7 2/4885 |
| US-20110213149-A1 | PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | BPNT1, GART, SLC7A1 | DPP4 1094/4885DPP8 1642/4885DPP7 1029/4885 |
| US-20100274017-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF | DPP4, DPP9, DPP8 | DPP4 1/4885DPP8 3/4885DPP7 5/4885 |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.